{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:46:12Z","timestamp":1790718372841,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1053\/j.ajkd.2013.01.022","type":"journal-article","created":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T00:36:09Z","timestamp":1364344569000},"page":"1026-1031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Dasatinib-Induced Nephrotic-Range Proteinuria"],"prefix":"10.1053","volume":"61","author":[{"given":"Eric","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lyndon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Chumley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar A.","family":"Jaimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1053\/j.ajkd.2013.01.022_bib1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2013.01.022_bib2","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1046\/j.1523-1755.2001.0590041324.x","article-title":"PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis","volume":"59","author":"Gilbert","year":"2001","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2013.01.022_bib3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1681\/ASN.2008010036","article-title":"Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis","volume":"20","author":"Iyoda","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2013.01.022_bib4","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1016\/j.transproceed.2006.10.083","article-title":"Early short-term platelet-derived growth factor inhibition prevents the development of chronic allograft nephropathy in experimental rat kidney transplantation","volume":"38","author":"Savikko","year":"2006","journal-title":"Transplant Proc"},{"issue":"9","key":"10.1053\/j.ajkd.2013.01.022_bib5","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1093\/ndt\/gfq790","article-title":"Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy","volume":"26","author":"Savikko","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2013.01.022_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.04-2370com","article-title":"Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo","volume":"19","author":"Wang","year":"2005","journal-title":"FASEB J"},{"issue":"1","key":"10.1053\/j.ajkd.2013.01.022_bib7","doi-asserted-by":"crossref","first-page":"F142","DOI":"10.1152\/ajprenal.00320.2009","article-title":"Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis","volume":"298","author":"Wang","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1053\/j.ajkd.2013.01.022_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.ki.5001528","article-title":"Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease","volume":"70","author":"Zoja","year":"2006","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2013.01.022_bib9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1681\/ASN.2004050392","article-title":"Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice","volume":"16","author":"Lassila","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2013.01.022_bib10","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1681\/ASN.2009090991","article-title":"Inhibition of podocyte FAK protects against proteinuria and foot process effacement","volume":"21","author":"Ma","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2013.01.022_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1440-1797.2011.01451.x","article-title":"Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy","volume":"16","author":"Advani","year":"2011","journal-title":"Nephrology"},{"issue":"8","key":"10.1053\/j.ajkd.2013.01.022_bib12","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1681\/ASN.2010111158","article-title":"Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease","volume":"22","author":"Iyoda","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2013.01.022_bib13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2013.01.022_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/ncpneph0476","article-title":"Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma","volume":"3","author":"Roncone","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2013.01.022_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.111.173559","article-title":"The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system","volume":"58","author":"Kappers","year":"2011","journal-title":"Hypertension"},{"issue":"19","key":"10.1053\/j.ajkd.2013.01.022_bib16","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","article-title":"Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors","volume":"15","author":"Demetri","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.ajkd.2013.01.022_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/08860220903391226","article-title":"Acute renal failure under dasatinib therapy","volume":"32","author":"Ozkurt","year":"2010","journal-title":"Renal Fail"},{"issue":"2","key":"10.1053\/j.ajkd.2013.01.022_bib18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.leukres.2008.07.029","article-title":"Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia","volume":"33","author":"Holstein","year":"2009","journal-title":"Leuk Res"},{"issue":"3","key":"10.1053\/j.ajkd.2013.01.022_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2007.01.006","article-title":"Vascular endothelial growth factor (VEGF) signaling in tumor progression","volume":"62","author":"Roskoski","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2, pt 2","key":"10.1053\/j.ajkd.2013.01.022_bib20","first-page":"F240","article-title":"Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney","volume":"268","author":"Simon","year":"1995","journal-title":"Am J Physiol"},{"issue":"5","key":"10.1053\/j.ajkd.2013.01.022_bib21","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1053\/j.ajkd.2013.01.022_bib22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2013.01.022_bib23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/jcp.52.10.735","article-title":"Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation","volume":"52","author":"Bailey","year":"1999","journal-title":"J Clin Pathol"},{"issue":"10","key":"10.1053\/j.ajkd.2013.01.022_bib24","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1093\/ndt\/gfq200","article-title":"Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans","volume":"25","author":"Hohenstein","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 2","key":"10.1053\/j.ajkd.2013.01.022_bib25","first-page":"S62","article-title":"Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer","volume":"4","author":"Hurwitz","year":"2004","journal-title":"Clin Colorect Cancer"},{"issue":"5","key":"10.1053\/j.ajkd.2013.01.022_bib26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajo.2009.06.014","article-title":"Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies","volume":"148","author":"Csaky","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1053\/j.ajkd.2013.01.022_bib27","first-page":"2408","article-title":"VEGF-initiated blood-retinal barrier breakdown in early diabetes","volume":"42","author":"Qaum","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1053\/j.ajkd.2013.01.022_bib28","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/j.ajkd.2010.11.030","article-title":"Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors","volume":"57","author":"Pelle","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2013.01.022_bib29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1053\/j.ajkd.2013.01.022_bib30","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.ophtha.2007.02.021","article-title":"Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration","volume":"114","author":"Apte","year":"2007","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1053\/j.ajkd.2013.01.022_bib31","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib","volume":"24","author":"Bollee","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2013.01.022_bib32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jnci\/djm311","article-title":"A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib","volume":"100","author":"Patel","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1053\/j.ajkd.2013.01.022_bib33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000241551","article-title":"Nephrotic syndrome and acute renal failure apparently induced by sunitinib","volume":"2","author":"Chen","year":"2009","journal-title":"Case Rep Oncol"},{"issue":"2","key":"10.1053\/j.ajkd.2013.01.022_bib34","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s10157-011-0543-9","article-title":"Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction","volume":"16","author":"Takahashi","year":"2012","journal-title":"Clin Exp Nephrol"},{"key":"10.1053\/j.ajkd.2013.01.022_bib35","doi-asserted-by":"crossref","first-page":"710216","DOI":"10.1155\/2011\/710216","article-title":"Development of nephrotic syndrome after administration of sorafenib in a case of metastatic renal cell carcinoma","volume":"2011","author":"Okuno","year":"2011","journal-title":"Case Rep Med"},{"issue":"4","key":"10.1053\/j.ajkd.2013.01.022_bib36","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10157-009-0167-5","article-title":"Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma","volume":"13","author":"Jonkers","year":"2009","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2013.01.022_bib37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2215\/CJN.08111109","article-title":"Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor","volume":"5","author":"Robinson","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"19","key":"10.1053\/j.ajkd.2013.01.022_bib38","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1158\/1078-0432.CCR-09-1717","article-title":"Rapid development of hypertension by sorafenib: toxicity or target?","volume":"15","author":"Humphreys","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.ajkd.2013.01.022_bib39","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.cellbio.13.1.513","article-title":"Cellular functions regulated by Src family kinases","volume":"13","author":"Thomas","year":"1997","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"3","key":"10.1053\/j.ajkd.2013.01.022_bib40","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1078-0432.CCR-09-1486","article-title":"Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment","volume":"16","author":"Liang","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"46","key":"10.1053\/j.ajkd.2013.01.022_bib41","doi-asserted-by":"crossref","first-page":"39933","DOI":"10.1074\/jbc.M111.241620","article-title":"Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes","volume":"286","author":"Bertuccio","year":"2011","journal-title":"J Biol Chem"},{"issue":"23","key":"10.1053\/j.ajkd.2013.01.022_bib42","doi-asserted-by":"crossref","first-page":"20716","DOI":"10.1074\/jbc.M301689200","article-title":"Fyn binds to and phosphorylates the kidney slit diaphragm component nephrin","volume":"278","author":"Verma","year":"2003","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1053\/j.ajkd.2013.01.022_bib43","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1172\/JCI60070","article-title":"Crk1\/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease","volume":"122","author":"George","year":"2012","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1053\/j.ajkd.2013.01.022_bib44","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2013.01.022_bib45","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.2010020167","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2013.01.022_bib46","author":"Jefferson"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638613004770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638613004770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:06:30Z","timestamp":1759457190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638613004770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0272638613004770"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2013.01.022","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dasatinib-Induced Nephrotic-Range Proteinuria","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2013.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}